DarioHealth (DRIO) vs Pulmonx (LUNG)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Pulmonx (LUNG) has outperformed DarioHealth (DRIO) over the past year, gaining 1.7% versus a loss of 66.8%. Over five years, LUNG leads with a -95.5% price change compared with -98.3% for DRIO. Pulmonx is the larger company by market cap ($78.4 million vs $56.8 million), about 1.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DRIO | LUNG |
|---|---|---|
| Share price | $5.80 | $1.83 |
| Market cap | $56.84M | $78.38M |
| 1-day change | +4.69% | +0.83% |
| YTD return | -52.28% | -18.10% |
| 1-year return | -66.83% | +1.69% |
| 5-year return | -98.32% | -95.45% |
| EPS (TTM) | $-2.28 | $-1.15 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $16.50 | $2.89 |
| 52-week low | $5.37 | $1.13 |
| Distance from 52-week high | -64.85% | -36.85% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +134.48% | +86.30% |
| Average volume | 25.00K | 477.26K |
| Shares outstanding | 9.80M | 42.95M |
| Employees | 160 | 296 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LUNG has outperformed DRIO by 68.5 percentage points over the past year.
About DarioHealth
DRIO stock →DarioHealth Corp. operates as a digital health company in the United States and internationally.
Health Care · Medical/Dental Instruments · 160 employees
About Pulmonx
LUNG stock →Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobronchial Valve; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.
Health Care · Medical/Dental Instruments · 296 employees
DRIO vs LUNG FAQ
Which is bigger, DarioHealth or Pulmonx?
Pulmonx (LUNG) is larger, with a market capitalization of $78.38M compared with $56.84M for DarioHealth (DRIO).
Which stock has performed better over the past year, DRIO or LUNG?
LUNG returned +1.69% over the past 12 months, compared with -66.83% for DRIO (price return, excluding dividends). Past performance does not predict future results.
Are DarioHealth and Pulmonx in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.